{
    "clinical_study": {
        "@rank": "21961", 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine whether pegaptanib sodium (Macugen) is safe and\n      effective in slowing the leakage of fluid within the retina and thereby stabilizing or\n      improving vision when compared to placebo injections.  A total of 176 patients will be\n      enrolled"
        }, 
        "brief_title": "Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula", 
        "completion_date": "February 2005", 
        "condition": "Diabetic Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients with clinically significant DME, VA 20/50-20/320 in the study eye and 20/100 in\n        the fellow eye"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "0", 
        "firstreceived_date": "June 24, 2002", 
        "id_info": {
            "nct_id": "NCT00040313", 
            "org_study_id": "EOP1005"
        }, 
        "intervention": {
            "intervention_name": "pegaptanib sodium (Macugen)", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 2, 2006", 
        "official_title": "A Phase II Randomized, Controlled, Double-Masked, Dose-Finding, Multi-Center, Comparative Trial, in Parallel Groups, to Establish the Safety and Preliminary Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer), Given Every 6 Weeks for 12 to 30 Weeks to Patients With Clinically Significant Diabetic Macular Edema (CSME) Involving the Center of the Macula", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00040313"
        }, 
        "source": "Eyetech Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eyetech Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2006"
    }, 
    "geocoordinates": {}
}